Darunavir Patent Expiration

Darunavir is Used for treating HIV infection in both adult and pediatric patients. It was first introduced by Janssen Products Lp in its drug Prezista on Jun 23, 2006. 10 different companies have introduced drugs containing Darunavir.


Darunavir Patents

Given below is the list of patents protecting Darunavir, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Prezista US7700645

(Pediatric)

Pseudopolymorphic forms of a HIV protease inhibitor Jun 26, 2027 Janssen Prods
Prezista US7700645 Pseudopolymorphic forms of a HIV protease inhibitor Dec 26, 2026 Janssen Prods
Prezista US8518987

(Pediatric)

Pseudopolymorphic forms of a HIV protease inhibitor Aug 16, 2024

(Expired)

Janssen Prods
Prezista US8518987 Pseudopolymorphic forms of a HIV protease inhibitor Feb 16, 2024

(Expired)

Janssen Prods
Prezista US7470506

(Pediatric)

Fitness assay and associated methods Dec 23, 2019

(Expired)

Janssen Prods
Prezista US8597876

(Pediatric)

Method of treating HIV infection Dec 23, 2019

(Expired)

Janssen Prods
Prezista US9889115

(Pediatric)

Fitness assay and associated methods Dec 23, 2019

(Expired)

Janssen Prods
Prezista US7470506 Fitness assay and associated methods Jun 23, 2019

(Expired)

Janssen Prods
Prezista US8597876 Method of treating HIV infection Jun 23, 2019

(Expired)

Janssen Prods
Prezista US9889115 Fitness assay and associated methods Jun 23, 2019

(Expired)

Janssen Prods
Prezista USRE43596

(Pediatric)

α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Nov 09, 2017

(Expired)

Janssen Prods
Prezista USRE43596 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors May 09, 2017

(Expired)

Janssen Prods
Prezista USRE42889

(Pediatric)

α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Apr 19, 2017

(Expired)

Janssen Prods
Prezista USRE43802

(Pediatric)

α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Apr 19, 2017

(Expired)

Janssen Prods
Prezista US6037157

(Pediatric)

Method for improving pharmacokinetics Dec 26, 2016

(Expired)

Janssen Prods
Prezista US6703403

(Pediatric)

Method for improving pharmacokinetics Dec 26, 2016

(Expired)

Janssen Prods
Prezista USRE42889 α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Oct 19, 2016

(Expired)

Janssen Prods
Prezista USRE43802 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Oct 19, 2016

(Expired)

Janssen Prods
Prezista US6037157 Method for improving pharmacokinetics Jun 26, 2016

(Expired)

Janssen Prods
Prezista US6703403 Method for improving pharmacokinetics Jun 26, 2016

(Expired)

Janssen Prods
Prezista US5843946

(Pediatric)

α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Jun 01, 2016

(Expired)

Janssen Prods
Prezista US5843946 α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Dec 01, 2015

(Expired)

Janssen Prods
Prezista US6248775

(Pediatric)

α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Feb 13, 2015

(Expired)

Janssen Prods
Prezista US6248775 α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors Aug 13, 2014

(Expired)

Janssen Prods
Prezista US6335460

(Pediatric)

α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors Feb 25, 2013

(Expired)

Janssen Prods
Prezista US6335460 α-and β-amino acid hydroxyethlamino sulfonamides useful as retroviral protease inhibitors Aug 25, 2012

(Expired)

Janssen Prods



Darunavir's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Darunavir Generics

Several generic applications have been filed for Darunavir. The first generic version for Darunavir was by Teva Pharmaceuticals Usa Inc and was approved on Nov 21, 2017. And the latest generic version is by Zydus Lifesciences Ltd and was approved on Dec 13, 2023.

Given below is the list of companies who have filed for Darunavir generic.


1. AMNEAL

Amneal Eu Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Amneal.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Dec 8, 2023
800MG tablet Prescription ORAL AB Dec 8, 2023


2. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Nov 28, 2023
800MG tablet Prescription ORAL AB Nov 28, 2023


3. CIPLA

Cipla Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Nov 28, 2023
800MG tablet Prescription ORAL AB Nov 28, 2023


4. DR REDDYS

Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Dr Reddys.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Nov 28, 2023
800MG tablet Prescription ORAL AB Nov 28, 2023


5. HETERO LABS LTD III

Hetero Labs Ltd Unit Iii has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.

Strength Dosage Form Availability Application Pathway TE code Launch Date
400MG tablet Prescription ORAL N/A Sep 14, 2023
600MG tablet Prescription ORAL AB Sep 14, 2023


6. LUPIN LTD

Lupin Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Lupin Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Sep 29, 2022
800MG tablet Prescription ORAL AB Sep 29, 2022


7. MSN

Msn Laboratories Private Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Msn.

Strength Dosage Form Availability Application Pathway TE code Launch Date
800MG tablet Prescription ORAL AB Nov 28, 2023
600MG tablet Prescription ORAL AB Nov 28, 2023


8. TEVA PHARMS USA

Teva Pharmaceuticals Usa Inc has filed for 1 generic for Darunavir. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Nov 21, 2017


9. ZYDUS LIFESCIENCES

Zydus Lifesciences Ltd has filed for 2 different strengths of generic version for Darunavir. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
600MG tablet Prescription ORAL AB Dec 13, 2023
800MG tablet Prescription ORAL AB Dec 13, 2023